Overview

Update
Total Equity Funding
$114.24M in 6 Rounds from 12 Investors
Most Recent Funding
$68M Series C on April 13, 2016
Headquarters:
Waltham, MA
Description:
Kala Pharmaceuticals develops novel treatments for diseases that affect mucosal tissues.
Founders:
,
Categories:
Pharmaceutical, Biotechnology, Medical
Website:
http://www.kalarx.com
Social:

Company Details

Update

Kala Pharmaceuticals is developing novel treatments for diseases that affect mucosal tissues. The company's proprietary mucus penetrating particle technology dramatically improves drug distribution and pharmacokinetics by uniformly coating the mucosal surface with biocompatible, drug-loaded particles. Kala's formulations achieve high, sustained local drug concentrations with reduced systemic exposure and are delivered in a patient friendly format. The company's research efforts have demonstrated successful in vivo proof-of-concept in mucosal organs such as the respiratory tract, eye, and cervicovaginal tract, enabling diverse product opportunities that target significant clinical unmet need. Kala is focused on advancing an internal pipeline of products through human proof-of-concept, while establishing R&D collaborations with select partners to improve products in their pipelines.

Funding Rounds (6) - $114.24M

Update
DateAmount / RoundValuationLead InvestorInvestors
Apr, 2016$68M / Series C7
Apr, 2014$22.5M / Series B6
Feb, 2013$11.5M / Series A4
Mar, 2012$7.24M / Private Equity4
Nov, 2010$3M / Venture0
Dec, 2009$2M / Series A0

Current Team (8)

Update

Offices/Locations (2)

Update
  • Headquarters

    100 Beaver St.

    Suite 201

    Waltham, MA 02453

    USA

  • Office

    135 Beaver St., Suite 309

    Waltham, MA 02452

    USA

Past Team (2)

Update

Images (2)

Update

Add Acquisitions

Add Products

Add Sub Organizations

Add Competitors

Add Memberships

Add Customers

Add Partners

Add Videos